UNIGE document Scientific Article - Review
previous document  unige:45062  next document
add to browser collection

Hormone de croissance et carcinogenèse: le point sur la question

Raguso, Comasia
Published in Revue médicale de la Suisse romande. 2003, vol. 123, no. 6, p. 397-400
Abstract Over the past 20 years, the use of recombinant growth hormone (rhGH) has become more frequent and the indications for this therapy extended to more common conditions than primary pituitary dysfunction. GH, a very strong anabolic agent, alters body growth and composition, and metabolic pathways. RhGH therapy seems to be beneficial in certain types of pathologies and surgical procedures, by preventing the deleterious effects due to catabolism and by increasing immune function, healing process and muscular strength. Several types of tumors have been studied to investigate the rhGH-related oncological risks. This article aims at reviewing the clinical studies focused on the possible association between rhGH and cancer.
Keywords Growth Hormone/adverse effects/physiologyHumansNeoplasms/etiology
PMID: 15095681
Full text
Article (Published version) (496 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research groups Chirurgie viscérale (104)
Chirurgie viscérale (HUG)
Nutrition clinique (597)
Groupe Giacobino Ariane (génétique) (923)
(ISO format)
GOTTRAUX, Sophie Aline et al. Hormone de croissance et carcinogenèse: le point sur la question. In: Revue médicale de la Suisse romande, 2003, vol. 123, n° 6, p. 397-400. https://archive-ouverte.unige.ch/unige:45062

315 hits

0 download


Deposited on : 2015-01-13

Export document
Format :
Citation style :